1. Home
  2. UTF vs IBRX Comparison

UTF vs IBRX Comparison

Compare UTF & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Infrastructure Fund Inc

UTF

Cohen & Steers Infrastructure Fund Inc

HOLD

Current Price

$24.93

Market Cap

2.4B

Sector

Finance

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$5.47

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTF
IBRX
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.6B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UTF
IBRX
Price
$24.93
$5.47
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$11.50
AVG Volume (30 Days)
171.7K
26.5M
Earning Date
01-01-0001
03-02-2026
Dividend Yield
7.19%
N/A
EPS Growth
N/A
N/A
EPS
2.84
N/A
Revenue
$138,636,669.00
$82,555,000.00
Revenue This Year
N/A
$667.58
Revenue Next Year
N/A
$92.92
P/E Ratio
$9.16
N/A
Revenue Growth
19.80
1025.95
52 Week Low
$22.05
$1.83
52 Week High
$26.53
$5.58

Technical Indicators

Market Signals
Indicator
UTF
IBRX
Relative Strength Index (RSI) 67.69 92.86
Support Level $23.86 $1.95
Resistance Level $24.50 $2.29
Average True Range (ATR) 0.26 0.28
MACD 0.07 0.30
Stochastic Oscillator 92.44 98.48

Price Performance

Historical Comparison
UTF
IBRX

About UTF Cohen & Steers Infrastructure Fund Inc

Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: